Scleromyxedema, a therapeutic dilemma
Related Experiment Video
Updated: Apr 15, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Julio Cesar Salas-Alanis1, Brayant Martinez-Jaramillo2, Minerva Gomez-Flores2
1Basic Science, School of Medicine, Universidad de Monterrey, Nuevo León, Mexico, USA.
Abstract:
Scleromyxedema is characterized by indurated erythematous papules disseminated on the face, chest and limbs. About twenty cases treated with thalidomide, stem cells, melphalan and immunoglobulin with varying results have been described. We present the case of a 28-year-old male patient diagnosed with scleromyxedema not associated with monoclonal gammopathy, multi-treated with anti-leprosy drugs, UVA1, and thalidomide for 4 years with no improvement.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Pericarditis III: Medical Management
Venous Thrombosis IV: Nursing Management